| Uchenna E Aguwa, DO | |
|
2400 Mt. Zion Parkway, Kaiser Permanente Southwood Medical Center, Jonesboro, GA 30236 | |
| (770) 603-3668 | |
| (740) 374-1693 |
| Full Name | Uchenna E Aguwa |
|---|---|
| Gender | Female |
| Speciality | Emergency Medicine |
| Experience | 18 Years |
| Location | 2400 Mt. Zion Parkway, Jonesboro, Georgia |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1164625950 | NPI | - | NPPES |
| 38100017862 | Medicaid | WV | |
| 2949117 | Medicaid | OH | |
| P00997170 | Other | OH | RRMCR |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 34009380 (Ohio) | Secondary |
| 207P00000X | Emergency Medicine | 072443 (Georgia) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| The Southeast Permanente Medical Group | 6204829013 | 576 |
News Archive
It is well-known that victims of bullying can have higher risks of future health and social problems. However, different victims experience a broad range of responses and some may not suffer at all.
Neuroblastoma tumors shrank, some dramatically, in 80 percent of newly diagnosed, young, high-risk patients enrolled in a Phase II clinical trial that included an experimental monoclonal antibody. The immunotherapy agent was produced on the St. Jude Children's Research Hospital campus where the study is still underway.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) announced today that it received a Complete Response letter from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for tapentadol extended release tablets.
The Cancer Prevention and Research Institute of Texas (CPRIT), the second largest funding source of cancer research in the United States, kicks off its second year by awarding 52 cancer research grants totaling $40,302,026 to 13 Texas institutions. Among the grants are two CPRIT Scholars in Cancer Research recruitment awards bringing outstanding scientists from preeminent institutions to join the faculty at Texas universities.
Not everyone needs a genetic test before taking the cancer drug irinotecan, and the U.S. Food and Drug Administration should modify its prescription guidelines to say so, according to researchers at the University of North Carolina at Chapel Hill.
› Verified 8 days ago
| Entity Name | The Southeast Permanente Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1245266956 PECOS PAC ID: 6204829013 Enrollment ID: O20040407000370 |
News Archive
It is well-known that victims of bullying can have higher risks of future health and social problems. However, different victims experience a broad range of responses and some may not suffer at all.
Neuroblastoma tumors shrank, some dramatically, in 80 percent of newly diagnosed, young, high-risk patients enrolled in a Phase II clinical trial that included an experimental monoclonal antibody. The immunotherapy agent was produced on the St. Jude Children's Research Hospital campus where the study is still underway.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) announced today that it received a Complete Response letter from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for tapentadol extended release tablets.
The Cancer Prevention and Research Institute of Texas (CPRIT), the second largest funding source of cancer research in the United States, kicks off its second year by awarding 52 cancer research grants totaling $40,302,026 to 13 Texas institutions. Among the grants are two CPRIT Scholars in Cancer Research recruitment awards bringing outstanding scientists from preeminent institutions to join the faculty at Texas universities.
Not everyone needs a genetic test before taking the cancer drug irinotecan, and the U.S. Food and Drug Administration should modify its prescription guidelines to say so, according to researchers at the University of North Carolina at Chapel Hill.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Uchenna E Aguwa, DO 3495 Piedmont Road, Ne, Nine Piedmont Center, Atlanta, GA 30305 Ph: (404) 364-7070 | Uchenna E Aguwa, DO 2400 Mt. Zion Parkway, Kaiser Permanente Southwood Medical Center, Jonesboro, GA 30236 Ph: (770) 603-3668 |
News Archive
It is well-known that victims of bullying can have higher risks of future health and social problems. However, different victims experience a broad range of responses and some may not suffer at all.
Neuroblastoma tumors shrank, some dramatically, in 80 percent of newly diagnosed, young, high-risk patients enrolled in a Phase II clinical trial that included an experimental monoclonal antibody. The immunotherapy agent was produced on the St. Jude Children's Research Hospital campus where the study is still underway.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) announced today that it received a Complete Response letter from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for tapentadol extended release tablets.
The Cancer Prevention and Research Institute of Texas (CPRIT), the second largest funding source of cancer research in the United States, kicks off its second year by awarding 52 cancer research grants totaling $40,302,026 to 13 Texas institutions. Among the grants are two CPRIT Scholars in Cancer Research recruitment awards bringing outstanding scientists from preeminent institutions to join the faculty at Texas universities.
Not everyone needs a genetic test before taking the cancer drug irinotecan, and the U.S. Food and Drug Administration should modify its prescription guidelines to say so, according to researchers at the University of North Carolina at Chapel Hill.
› Verified 8 days ago
Lynn Kevin Flowers, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 2400 Mt. Zion Parkway, Kaiser Permanente Southwood Medical Center, Jonesboro, GA 30236 Phone: 770-603-3668 Fax: 912-691-1953 | |
Joseph Paul Brissette, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 2400 Mount Zion Pkwy, Kaiser Permanente Southwood Medical Center, Jonesboro, GA 30236 Phone: 770-603-3649 Fax: 770-994-4747 | |
Dr. Stanley Llewellyn Allen Iii, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 2400 Mt. Zion Parkway Kaiser Permanente, Southwood Comprehensive Medical Center, Jonesboro, GA 30236 Phone: 770-365-0966 | |
Shakira N. Thomas, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 2400 Mount Zion Pkwy, Kaiser Permanente Southwood Medical Center, Jonesboro, GA 30236 Phone: 205-616-5289 | |
Dr. Michele Renee Hayek, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 2400 Mt. Zion Parkway, Kaiser Permanente, Jonesboro, GA 30236 Phone: 770-603-3649 | |
Dr. Angie Harshaw Harris, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 2400 Mount Zion Pkwy, Kaiser Permanente Southwood Comprehensive Medical Cente, Jonesboro, GA 30236 Phone: 770-603-3668 |